Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Aduhelm

Chemical Nameaducanumab-avwa
Dosage FormInjection (intravenous; 170 mg/1.7 mL, 300 mg/3 mL)
Drug ClassMonoclonal antibodies
SystemNervous
CompanyBiogen
Approval Year2021

Indication

  • For the treatment of Alzheimer’s disease
Last updated on 5/2/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Aduhelm (aducanumab-avwa) Prescribing Information.2022Biogen Inc., Cambridge, MA
Document TitleYearSource
Amyloid-related imaging abnormalities and β-amyloid-targeting antibodies: a systematic review. 2022JAMA Neurology
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease.2021Ageing Research Reviews
Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review. 2021Ageing Research Reviews